Carbarmazepine
PreclinicalSmall molecule
Carbarmazepine is one of 22 small molecule programs targeting Trigeminal Neuralgia. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
38 competitors in Trigeminal Neuralgia
#DrugCompanyPhaseTrials
1Tegretol
NovartisApproved
Trileptal
NovartisApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Lamictal
GGlaxo Dba Glaxosmithkline
Approved
Intuniv
PPromius Pharma, LLC
Approved
Botox
RRevance Therapeutics, Inc.
Phase 3
Ethyol
LLegacy Health System
Phase 3
Botulinum Toxin a
GSKPhase 3
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Nurtec
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Carbarmazepine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- YYuanyuan Wu